Type
Text
Type
Thesis
Advisor
Ngai, Ming-Yu. | Ojima, Iwao | Rudick, Jonathan
Date
2014-05-01
Keywords
Biological Evaluation, MTT assay, Synthesis, Taxoids | Chemistry
Department
Department of Chemistry.
Language
en_US
Source
This work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree.
Identifier
http://hdl.handle.net/11401/77830
Publisher
The Graduate School, Stony Brook University: Stony Brook, NY.
Format
application/pdf
Abstract
Cancer is a group of diseases leading by uncontrolled cell growth, and is responsible for approximately one in four deaths in the United States. While significant advancements have been made in chemotherapy, combating drug resistant strains have remained a major challenge. Traditional chemotherapeutic agents, Taxol® and Taxotere®, have showed little efficacy in treating melanoma, pancreatic, gastric, brain and renal cancers. Also, in clinical treatment, repeated administration of Taxol® may lead to multi-drug resistance (MDR) phenomenon. Therefore, it is essential to develop new taxoid anticancer agents with superior pharmacological properties, fewer side effects, and improved potency against various classes of tumors, and in particular drug-sensitive and drug-resistant cancers. On the basis of our structure-activity relationship (SAR) studies on the taxane class, three highly potent compounds - second generation taxoids SB-T-1214 and SB-T-1212N1 and third generation fluorotaxoid SB-T-121405 - were synthesized via Ojima-Holton coupling reaction using corresponding β -lactams and 10-DAB derivatives. The enantiopure β -lactams were prepared through a chiral ester enolate-imine cyclocondensation utilizing Whitesell's chiral auxiliary. The biological evaluation of taxoids by in vitro cytotoxicity assays was performed by MTT assay in cancer and drug-resistant cancer cell lines. Paclitaxel, docetaxel, SB-T-1214, and SB-T-1216 were used as control standards to evaluate the potency of eight newly synthesized taxoids, i.e. | SB-T-0035, 10-Ac-docetaxel, SB-T-1211, SB-T-1212N1, SB-T-121405, SB-T-12822-6, SB-T-121406, and SB-T-12852-6. Among these compounds, SB-T-121405, with a m-OCF3 substitution at the C2 position of the taxoid, showed the highest activity against human breast carcinoma cancer cell line, MCF-7, and metastatic ovarian tumor cell line, NCI-ADR-RES. | 134 pages
Recommended Citation
Wang, Xin, "Synthesis and Biological Evaluation of Second and Third Generation of Taxoid Anticancer Agents" (2014). Stony Brook Theses and Dissertations Collection, 2006-2020 (closed to submissions). 3597.
https://commons.library.stonybrook.edu/stony-brook-theses-and-dissertations-collection/3597